BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 30, 2026
Home » CSL Ltd.

Articles Tagged with ''CSL Ltd.''

Test tubes with blood samples

CSL pact intact as Uniqure works to FIX hemophilia B gene therapy stall

Dec. 21, 2020
By Randy Osborne
Amsterdam-based Uniqure NV’s regulatory hitch with its highly regarded hemophilia B program had analysts questioning during a conference call what the development might mean for the company’s deal with CSL Ltd.
Read More
Disintegrating coronavirus

CSL, University of Queensland quit COVID-19 vaccine trials due to HIV antibody response

Dec. 15, 2020
By Tamra Sami
PERTH, Australia – The University of Queensland (UQ) and CSL Ltd. are abandoning their trials of an Australian COVID-19 vaccine after recipients generated HIV antibodies during phase I trials. The response means the antibodies produced by the vaccine can interfere with HIV diagnostic tests. However, there was no possibility the vaccine caused infection, and routine follow-up tests confirmed no HIV virus was present, the partners said.
Read More
Disintegrating coronavirus

CSL, University of Queensland quit COVID-19 vaccine trials due to HIV antibody response

Dec. 11, 2020
By Tamra Sami
PERTH, Australia – The University of Queensland (UQ) and CSL Ltd. are abandoning their trials of an Australian COVID-19 vaccine after recipients generated HIV antibodies during phase I trials. The response means the antibodies produced by the vaccine can interfere with HIV diagnostic tests. However, there was no possibility the vaccine caused infection, and routine follow-up tests confirmed no HIV virus was present, the partners said.
Read More
Hand holding money plant

Ena Respiratory launches with AU$11.7M series A as it heads toward clinic with COVID-19 nasal spray

Sep. 29, 2020
By Tamra Sami
PERTH, Australia – Brandon Capital announced the launch of Ena Respiratory Pty Ltd., which has developed a nasal treatment to boost the natural immune system to fight common colds and flu and has proved successful in reducing COVID-19 viral replication.
Read More
Hand holding money plant

Ena Respiratory launches with AU$11.7M series A as it heads toward clinic with COVID-19 nasal spray

Sep. 28, 2020
By Tamra Sami
PERTH, Australia – Australia’s largest health care venture capital firm, Brandon Capital, announced the launch of Australian biotech company Ena Respiratory Pty Ltd., which has developed a nasal treatment to boost the natural immune system to fight common colds and flu and has proved successful in reducing COVID-19 viral replication.
Read More
Australian coins and bills

Aussie biopharmas undertake capital raisings to stay afloat as recession hits

Sep. 8, 2020
By Tamra Sami
PERTH, Australia – Australia’s biopharma sector fared better than the country at large at the end of the financial year that ended June 30, as the country saw GDP fall 7% in the final quarter, the largest drop since 1959. Australia’s trading relationship with China helped the country sidestep the global financial recession of 2008, but the recent divide between the U.S. and China is also putting a wedge between Australia and China relations.
Read More
Australian coins and bills

Aussie biopharmas undertake capital raisings to stay afloat as recession hits

Sep. 2, 2020
By Tamra Sami
PERTH, Australia – Australia’s biopharma sector fared better than the country at large at the end of the financial year that ended June 30, as the country saw GDP fall 7% in the final quarter, the largest drop since 1959.
Read More
Australia and coronavirus syringe

Australian government signs supply deal with Astrazeneca for COVID-19 Oxford vaccine

Aug. 25, 2020
By Tamra Sami
PERTH, Australia – As Victoria suffers through a second COVID-19 wave, bringing the death toll to 430 for Australia, Prime Minister Scott Morrison said that Australians could be among the first in the world to receive a COVID-19 vaccine through an agreement with Astrazeneca plc. Under the deal, every Australian would be able to receive AZD-1222, which is being developed with the University of Oxford.
Read More
Australia and coronavirus syringe

Australian government signs supply deal with Astrazeneca for COVID-19 Oxford vaccine

Aug. 19, 2020
By Tamra Sami
PERTH, Australia – As Victoria suffers through a second COVID-19 wave, bringing the death toll to 430 for Australia, Prime Minister Scott Morrison said that Australians could be among the first in the world to receive a COVID-19 vaccine through an agreement with Astrazeneca plc. Under the deal, every Australian would be able to receive AZD-1222, which is being developed with the University of Oxford.
Read More
Australia and coronavirus

Australia’s Brandon Capital calls on government to rescue decimated life sciences sector

June 19, 2020
By Tamra Sami
PERTH, Australia – Australia’s largest life science investment fund is pressing the government for an urgent COVID-19 response package to support the country’s AU$170 billion (US$117 billion) life sciences sector that is struggling to survive in a post-COVID-19 ecosystem.
Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing